Tiban Powder Veterinary Grade API is supplied as a non-sterile, compendial-grade active substance for further pharmaceutical processing into veterinary dosage forms including tablets, injectable solutions, capsules, oral powders, granules, medicated premixes, and liquid solutions. The article designation identifies the uncompounded API, not a finished dosage form. It is supplied in 25 kg HDPE drums with double low-density polyethylene liners, desiccant, and tamper-evident labelling; the label carries lot number, production date, retest date, gross/net weight, and the applicable pharmacopoeial or manufacturer monograph reference. Storage at ≤25 °C and ≤60% RH in the original unopened container is the standard condition for the manufacturer’s stability program; a retest interval of 24 months is common, but the lot-specific certificate of analysis remains the controlling document. The pharmacopoeial monograph and chemical structure are not established by this descriptive scope; the batch-specific certificate of analysis identifies the active substance and the applicable monograph or manufacturer specification. The material is not intended for direct administration to animals and must not be confused with a medicated premix or a finished solution.

What Distinguishes a Veterinary-Grade API from an Uncontrolled Technical Powder?

The controlling difference is release against pharmacopoeial and good-manufacturing-practice requirements, not merely a higher titre or price point. Production occurs under a quality system aligned with EU GMP Part II, 21 CFR 210/211, and ISO 9001:2015, with dedicated or campaign-cleaned equipment. Feed-grade or technical powders may be manufactured under less stringent hygiene and documentation controls; they are not released for identity, related substances, residual solvents, or endotoxin using the same pharmacopoeial methods. On production-scale ribbon blenders and fluid-bed dryers, uncontrolled powders often show segregation and unpredictable lot-to-lot particle size, whereas a veterinary-grade API is controlled for bulk density, tapped density, and particle-size distribution to maintain blend uniformity. Batch documentation includes a certificate of analysis, SDS, and stability data under ICH/VICH conditions; the API lot can be traced to the manufacturing campaign, raw-material lots, and cleaning-validation records.

Compared with liquid API concentrates, the powder form reduces transport mass and avoids residual solvent handling at the drug-product site, but it introduces dust-control and flowability constraints. Compared with microencapsulated or carrier-coated feed-grade powders, the uncoated veterinary-grade API is not directly admixed into final feed without a controlled dilution step; it must be weighed, blended, and formulated under pharmaceutical or premix GMP conditions.

Particle-size distribution is not a single value but a formulation-critical interval. For direct compression tablet lines operating on rotary presses with forced feeders at 60–80 rpm, an API with a Dv50 below 20 µm can increase sticking and require precompression force adjustment; a Dv90 above 250 µm can produce weight variability above 3% relative standard deviation. Laser diffraction per ISO 13320:2020 is used to control the volume distribution, while bulk and tapped density tests per Ph. Eur. 2.9.34 supply the Hausner ratio. A Hausner ratio below 1.25 is generally acceptable for direct compression; values above 1.35 indicate the need for dry or wet granulation. Milling is performed with a pin mill or cone mill under controlled feed rate; excessive mechanical energy can generate fines and amorphous surface domains, which alter flow and chemical stability. If the API is polymorphic or exists as a hydrate, differential scanning calorimetry per Ph. Eur. 2.2.34 and X-ray powder diffraction per Ph. Eur. 2.9.33 are used to verify that the crystal form remains unchanged after milling.

When Polymorphism, Moisture, and Particle Size Interact in Tablet and Premix Lines

When the same API lot must support both direct compression tablets and low-inclusion premixes, the specification is not a single point but a bounded design space. A moisture content above 0.5% by Karl Fischer titration Ph. Eur. 2.5.12 can cause sticking during tablet compression and promote hydrolysis in granulated formulations. A loss on drying above 0.5% by Ph. Eur. 2.2.32 may also indicate a hydrate transition, particularly if the material is stored in non-barrier packaging at >60% RH. Polymorphic identity is monitored against a reference diffractogram; a shift in the characteristic peaks after milling or wet granulation is a critical quality event because an uncontrolled change from a stable hydrate to an amorphous or anhydrous form can alter dissolution, bioavailability, and chemical stability. Published data for this specific configuration is limited; therefore, the manufacturer’s validated polymorph specification and the approved drug-product dossier provide the binding criteria.

Injectable-grade use imposes constraints that do not apply to tablet or premix manufacture. The API is dissolved or suspended in water for injection and filtered through a membrane with a pore size not exceeding 0.45 µm for sterilization by filtration, or 0.22 µm for relatively high bioburden control prior to terminal sterilization. Endotoxins are not removed by 0.22 µm filtration; therefore, the API must be released against a low-endotoxin criterion. The endotoxin limit for a parenteral product is calculated as K/M, with a default K of 5 EU/kg; the API limit is then back-calculated from the maximum dose and final batch volume. If the drug substance has limited water solubility, pH adjustment with pharmaceutically acceptable buffers or co-solvents such as propylene glycol or PEG 400 may be required. The resulting solution must be supported by forced-degradation data, filter-compatibility testing, and sub-visible particulate matter limits per Ph. Eur. 2.9.19. Non-sterile API is acceptable only because sterilization occurs downstream; if the API itself is claimed sterile, the manufacturer must provide sterility assurance data per Ph. Eur. 2.6.1.

A Seven-Route Release Matrix in One API: Process Boundaries and Control Measures

The same API lot can be used for tablets, capsules, powders, granules, injections, premixes, and solutions, but the process boundary is not interchangeable. Direct compression requires a compressible carrier such as microcrystalline cellulose and crospovidone; wet granulation with povidone or starch paste must be performed below the thermal decomposition threshold of the API. For premix manufacture, the active substance is diluted with a carrier such as lactose monohydrate, calcium carbonate, or corn cob meal in a ribbon blender or twin-shell blender; mixing time and fill volume are validated to achieve a coefficient of variation ≤5%. The following matrix summarises the minimum process-control expectations for each route.

Residual solvent control is route-dependent and must follow VICH GL18 or the corresponding pharmacopoeial chapter. Class 1 solvents must not be used; class 2 solvents require documented process capability below permitted daily exposure limits; class 3 solvents conform to 5000 ppm or the justified limit. During drying on a fluid-bed dryer, residual solvent removal is monitored by in-process loss on drying and gas chromatography per Ph. Eur. 2.2.28; a high-boiling solvent can retain at levels above the limit if the inlet temperature is too low or the residence time is too short. On a production batch, the drying curve should be generated to identify the point at which residual solvent plateaus. Heavy metal and elemental impurity limits are aligned with ICH Q3D; routine release may use inductively coupled plasma mass spectrometry instead of a simple colorimetric sulfide test because the route of administration and target species affect permitted daily exposure. Feed-grade powders are not necessarily controlled against these limits; therefore, substitution of an uncontrolled technical powder into a licensed formulation is a regulatory and safety infraction.

Stability of the uncompounded API is evaluated under long-term 25 °C/60% RH or 30 °C/65% RH conditions and accelerated 40 °C/75% RH per ICH/VICH guidance. Moisture-barrier packaging is required for shipments to climate zone IV; if the original liner is damaged, the material should be re-tested for moisture and related substances before use. A temporary spike in moisture above 0.5% without chemical degradation may be corrected by drying under validated conditions, but drying must not exceed the API’s thermal stability limit. Bulk API stored in partially used containers is more vulnerable to hydration and should be retested before formulation.

Where Granulation Fails: Segregation, Dusting, and Operator Exposure Limits

Where granulation fails or dry blending is performed without sufficient attention to particle-size matching, segregation occurs in downstream transfer. In a bin blender, segregation risk is reduced when the API particle size is matched to the carrier particle size within a factor of 3; larger mismatches allow percolation of fine particles to the bottom of the blender or dust collection points. On a production-scale rotary tablet press, an API with high dusting tendency can increase cross-contamination and require local exhaust ventilation. Air handling units serving the dispensing suite should maintain negative pressure relative to adjacent corridors. Total dust exposure limits for operators must be established according to occupational exposure banding; if the API has a low health-based exposure limit, dedicated dispensing booths with high-efficiency particulate air filtration are required. Cleaning validation swab limits should be derived from health-based exposure limits under regional guidance; rinsate sampling alone is insufficient for a poorly soluble API because surface residues may remain after aqueous cleaning. Solubility and degradation products in the cleaning solution should be understood before selecting a cleaning regimen.

For direct compression tablet lines, the API is pre-blended with microcrystalline cellulose and crospovidone in a bin blender operated at 60–80% fill volume; blend uniformity samples are taken at 10 locations using a thief sampler and tested per Ph. Eur. 2.9.40. A batch failing uniformity at the pre-blend stage is re-mixed for an additional 10 min; if the relative standard deviation remains above 5%, the batch is reworked by dry granulation. High-shear granulation with an impeller speed of 200–400 rpm and a chopper speed of 1500–3000 rpm may be used only after confirming that the heat generated does not exceed the API’s thermal stability limit. For aqueous injection, the API is added to water for injection under nitrogen blanketing if the molecule is oxygen-sensitive; dissolved oxygen is maintained below 0.5 mg/L by sparging with pharmaceutical-grade nitrogen, and the solution is protected from light until filling.